In these conditions, RAS blockers, such as ACEIs or ARBs, are life-saving drugs [9,11,12,14,15], but they were suggested to be detrimental in COVID-19 patients because they increase ACE2 expression [6,7]. Here, ACE2 is linked to COVID-19.